Ausdal Financial Partners’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Ausdal Financial Partners’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,380	Closed	-$44K	–	397
2017 Q4	$44K	Hold	10,380	–	–	0.02%	352
2017 Q3	$15K	Sell	10,380 -600	-5%	-$836	0.01%	333
2017 Q2	$16K	Hold	10,980	–	–	0.01%	314
2017 Q1	$28K	Hold	10,980	–	–	0.01%	288
2016 Q4	$28K	Sell	10,980 -500	-4%	-$1.44K	0.01%	257
2016 Q3	$35K	Hold	11,480	–	–	0.02%	262
2016 Q2	$37K	Sell	11,480 -250	-2%	-$916	0.02%	258
2016 Q1	$36K	Hold	11,730	–	–	0.02%	229
2015 Q4	$47K	Buy	+11,730	New	+$54K	0.02%	476

Other funds holding ECYT

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

Ausdal Financial Partners's ECYT Position: Q1 2018 in Review

Ausdal Financial Partners sold out of Endocyte, Inc. Common Stock (ECYT) in Q1 2018, closing a stake of 10,380 shares — an estimated $44K sold.

Ausdal Financial Partners first reported a position in ECYT in Q4 2015 and held it in 9 quarters. The position peaked at $47K in Q4 2015. 89 funds tracked by Wall St. Rank hold ECYT as of Q1 2018.

Ausdal Financial Partners reported no remaining Endocyte, Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Ausdal Financial Partners sold 10,380 Endocyte, Inc. Common Stock shares in Q1 2018, an estimated $44K.
Ausdal Financial Partners first reported a position in Endocyte, Inc. Common Stock in Q4 2015 and held it in 9 quarters.
Ausdal Financial Partners's Endocyte, Inc. Common Stock position peaked at $47K in Q4 2015.
89 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q1 2018.

Based on Ausdal Financial Partners's 13F filing for Q1 2018, filed 20 Apr 2018.